Abstract:We recently read the article by Tian et al with great interest.1 In their research, the authors compared the prognosis of patients with gastric and gastroesophageal junction adenocarcinoma who received perioperative chemoradiotherapy (PCRT) with those who received perioperative chemotherapy (POC) alone. The authors found that the addition of preoperative radiotherapy to POC appears to be associated with an increased risk of death in both the gastric and gastroesophageal junction adenocarcinoma subgroups. However, by reviewing previous studies and conducting an external validation based on the Surveillance, Epidemiology, and End Results (SEER) database, we found some contradicting results. Thus, we believe more caution should be exercised regarding any conclusions that additional radiotherapy increased the risk of death. In the majority of previous studies, a similar prognosis was demonstrated between the PCRT and the POC groups,2-4 a finding that contradicts the results published by Tian et al.1 Furthermore, if we focused on the patient with a T3 to T4 tumor, PCRT might have a positive influence on survival. For example, Stahl et al reported that in the Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET) trial (in which only patients with T3-T4 tumors were included),5 the PCRT group had a significantly improved progression-free survival (hazard ratio [HR], 0.37; P = .01) and the overall survival (OS) also demonstrated a positive trend (HR, 0.65; P = .055). Trying to investigate the result further, we conducted a validation study based on the SEER database, which also is nationwide. We included patients from 2004 through 2014 in the SEER database using the criteria of Tian et al.1 A total of 2201 patients finally were selected in our research, 934 of whom received PCRT and surgery, 336 of whom received POC, and 931 of whom underwent surgery alone. Pairwise 1:1 propensity score matching was performed to compare the survival outcomes among the 3 groups. It was shown that both the PCRT and the POC groups experienced a survival benefit compared with the group treated with surgery alone. However, there was no statistically significant difference noted with regard to the overall survival or cancer-specific survival between the PCRT and the POC groups. We also conducted a subgroup analysis using Cox regression. Within the population of patients with T3 to T4 disease, the PCRT group was found to have significantly improved prognosis compared with the surgery-alone group (HR, 0.44; 95% CI, 0.34-0.58 [P < .001]). Compared with the POC group, the result indicated a survival advantage for PCRT (HR, 0.74; 95% CI, 0.54-1.02 [P = .07]), although statistical significance was not achieved. In addition, it was shown that the PCRT group had a significantly better prognosis than both the POC and surgery-alone groups among patients with T3 to T4 disease and with positive lymph nodes (HRs of 0.65 and 0.44, respectively [P = .02 and P < .001, respectively]). Based on the above evidence, although the contradiction between the study by Tian et al1 and the previous ones remains difficult to explain, it is rational to assume that patients with advanced disease benefit more from radiotherapy. Thus, instead of concluding that radiotherapy may increase the risk, we believe a subgroup analysis is needed. In addition, the description of the tumor stage and patients' characteristics after propensity score matching may facilitate further discussion. No specific funding was disclosed. The authors made no disclosures.

The Survival Benefit from the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection.

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Adjuvant Chemoradiotherapy Versus Adjuvant Chemotherapy for Stage III Gastric or Gastroesophageal Junction Cancer After D2/R0 Resection

Can Chemoradiotherapy Improve Survival after an R1 Resection for Gastric Cancer: A Retrospective Study of a Chinese Cohort

D2-Resected Stage Iiic Gastric Cancer Patients Benefit from Adjuvant Chemoradiotherapy

Benefit from Adjuvant Chemoradiation to Resected Stage Iiic Gastric Cancer Patients with D2 Lymph Node Dissection

Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis

Adjuvant chemoradiotherapy versus adjuvant chemotherapy for R1 resected gastric cancer: a retrospective cohort study.

The Effectiveness of Gastrectomy with Chemoradiotherapy among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis

Improving Survival Of Stage Ii-Iii Primary Gastric Signet Ring Cell Carcinoma By Adjuvant Chemoradiotherapy

Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition

Patients with Gastroesophageal Junction Adenocarcinomas of an Advanced Stage May Benefit from Perioperative Chemoradiotherapy: A Validation Based on the Surveillance, Epidemiology, and End Results Database

Benefit Of Adjuvant Chemoradiotherapy In Patients With Pathological Stage Iii Gastric Cancer

Survival Benefit of Palliative Gastrectomy Followed by Chemotherapy in Stage IV Gastric Signet Ring Cell Carcinoma Patients: A Large Population‐based Study

Neoadjuvant Versus Adjuvant Radiotherapy for Resectable Locally Advanced Gastric Cancer: A SEER Population Analysis

Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy

Survival Benefits from Neoadjuvant Treatment in Gastric Cancer: a Systematic Review and Meta-Analysis

Adjuvant radiotherapy may have significant survival benefits for gastric cancer patients with 1-29 lymph nodes retrieved

Identification of Patients with Lymph Node Metastasis from Gastric Cancer Who May Benefit from Adjuvant Chemoradiotherapy after D2 Dissection-Do N3 Patients Benefit from Additional Radiation?

Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy for Local Advanced Gastric or Siewert II/III GEJ Cancer: A Retrospective Analysis.

Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis